Antibodies News and Research

RSS

Calluna Pharma successfully completes Phase 1 clinical study of CAL101, a first-in-class therapeutic for fibrotic and fibro-inflammatory indications

Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the completion of Phase 1 clinical study for CAL101, Calluna’s lead product candidate.

23 Oct 2024

Advancements in antibody-drug conjugates transform cancer therapy

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the potency of cytotoxic drugs.

22 Oct 2024

UK-DTOP tool promises improved outcomes for kidney transplant recipients

A new advanced artificial intelligence (AI) tool, developed by renal doctors internationally, represents a significant step forward in predicting and potentially improving outcomes for UK kidney transplant patients.

22 Oct 2024

New antibody targets cancer-causing HER2 mutations

For some proteins, a single mutation, or change in its DNA instructions, is all it takes to tip the balance between functioning normally and causing cancer.

22 Oct 2024

New single-chain mRNA vaccines offer enhanced immunity and protection against mpox

Study reveals single-chain mRNA vaccines confer 100% protection against lethal mpox challenge in mice, marking a significant advancement in vaccine technology.

22 Oct 2024

Novel antibodies show promise for tumor targeting and RAD51 inhibition

A new research paper was published in Oncotarget's Volume 15 on October 1, 2024, entitled, "Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition."

21 Oct 2024

Emory researchers discover enzyme to combat IgG-mediated disorders

Myasthenia gravis (MG) is a chronic autoimmune disorder in which antibodies block communication between nerves and muscle, resulting in weakness of the skeletal muscles.

21 Oct 2024

Sapio Sciences enhances lab informatics platform with new immunogenicity bioanalysis features

Sapio Sciences, the science-aware™ lab informatics platform, today announced the addition of new immunogenicity bioanalysis features to its industry-leading lab informatics platform.

18 Oct 2024

Trial evaluates monoclonal antibodies for long COVID prevention

The first randomized, placebo-controlled clinical trial evaluating the impact of therapeutic monoclonal antibodies on the risk of developing long COVID was led by researchers at Weill Cornell Medicine.

17 Oct 2024

Gum disease tied to higher thrombosis risk: Could periodontal therapy help save lives?

The connection between gum disease and thrombosis underscores the role of oral health in reducing thrombotic disease risk and improving patient outcomes.

17 Oct 2024

A deeper look at COVID-19 transmission and fetal health

A new Cleveland Clinic-led study published in The EMBO Journal shows that mild and asymptomatic SARS-CoV-2 infections can trigger immune responses in a pregnant individual that may cause serious inflammatory responses in the developing fetus.

17 Oct 2024

New handheld device promises rapid blood diagnostics

Patients who go to the doctor to provide a blood sample are typically faced with a needle and syringe and hours or days of waiting to get results back from a lab.

16 Oct 2024

Study provides detailed analysis of mRNA vaccine circulation and breakdown

A study led by researchers from RMIT University and the Doherty Institute has provided the first detailed analysis of how mRNA vaccines circulate and break down in the human bloodstream.

16 Oct 2024

Sapio Sciences enhances bioanalysis LIMS and ELN with advanced immunogenicity capabilities

Sapio Sciences, the science-aware™ lab informatics platform, today announced the addition of new immunogenicity bioanalysis features to its industry-leading lab informatics platform.

From Sapio Sciences 16 Oct 2024

Antibody engineering drives innovation in drug development

Monoclonal antibodies (mAbs) are used to prevent, detect, and treat a broad spectrum of non-communicable and communicable diseases. Over the past few years, the market for mAbs has grown exponentially with an expected compound annual growth rate (CAGR) of 11.07% from 2024 (237.64 billion USD estimated at the end of 2023) to 2033 (679.03 billion USD expected by the end of 2033).

16 Oct 2024